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What is the role of prostate-specific antigen (PSA) screen-
ing in prostate cancer? An expert panel produced these 
recommendations based on a linked systematic review.1 
The review was triggered by a large scale, cluster ran-
domised trial on PSA screening in men without a previous 
diagnosis of prostate cancer published in 2018 (box 1).2 It 
found no difference between one-time PSA screening and 
standard practice in prostate cancer mortality but found 
an increase in the detection of low risk prostate cancer 
after a median follow-up of 10 years.
Although the results of this study suggest screening 
is not worthwhile, several guidelines advocate offering 
screening in some cases. The study was much larger than 
previous studies, and existing trials had published more 
extended follow-up results, and the BMJ Rapid Recom-
mendations team felt these merited a new appraisal of 
the body of evidence. This guideline aims to promptly 
and transparently translate potentially practice-changing 
evidence to usable recommendations for clinicians and 
patients, based on the GRADE framework and following 
standards for trustworthy guidelines.
The panel suggests against systematic PSA screening 
(weak recommendation). The panel members judged that 
most men will decline screening because the benefit is 
small and uncertain and there are clear harms. However, 
there is likely considerable variation in values and prefer-
ences. Men with family history of prostate cancer, African 
descent or of lower socioeconomic status, having higher 
baseline risk of prostate cancer death, may be more likely 
to choose PSA screening. Shared decision-making is 
needed for men considering screening.
Box 2 shows all of the articles and evidence linked in 
this Rapid Recommendation package. The main info-
graphic provides an overview of the absolute benefits 
and harms of PSA screening. The table at the end of the 
article shows any evidence that has emerged since the 
publication of this guideline.
Current practice
Prostate cancer is one of the most common cancers 
in men and is the leading cause of cancer death in 24 
countries, ranking eighth globally, sixth in high income 
countries, and 12th in low income countries.3 Prostate 
cancer screening is with a PSA blood test. A raised PSA 
level can be a sign of prostate cancer but can also occur 
WHAT YOU NEED TO KNOW
•  PSA testing has increased the number of
men diagnosed with and treated for prostate
cancer, but many of these men would never
have experienced any symptoms or death
from prostate cancer
•  This guideline makes a weak
recommendation against offering systematic
PSA screening based on an updated
systematic review. The recommendation is
weak because there may be a small, though
uncertain, benefit of screening on prostate
cancer mortality
•  Men who place more value on avoiding
complications from biopsies and cancer
treatment are likely to decline screening. In
contrast, men who put more value in even a
small reduction of prostate cancer mortality
(such as men at high baseline risk because
of family history or African descent, or those
concerned to rule out the diagnosis) may opt
for screening
•  Shared decision making is needed for men
considering screening to make a decision
consistent with their individual values and
preferences. However, clinicians need not feel
obligated to systematically raise the issue of
PSA screening with their patients
Box 1 | Results of the CAP Randomized Clinical Trial2
This cluster-randomised trial of 419 582 British men was 
published in March 2018. After a median follow-up of 
10 years, there was no significant difference in prostate 
cancer-specific mortality in men receiving care by general 
practices randomised to a single PSA screening intervention 
compared with men receiving care by practices randomised 
to standard practice without screening. The detection of low 
risk prostate cancer cases was higher in the PSA screening 
group. Although the trial had limitations, such as low 
adherence to PSA testing in the intervention arm (36%) and 
a follow-up of only 10 years, its findings do not support the 
use of single PSA testing for population based screening.
The Rapid Recommendations executive felt this new 
study—taken together with extended follow-up data from 
existing trials—required a new appraisal of the body of 
evidence for patients and clinicians.
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Men with these characteristics 
carry a higher incidence of prostate 
cancer, and could be at higher risk 
of dying of prostate cancer. It 
remains uncertain whether the 
impact of screening is similar in 
these higher risk men in 
comparison to men at lower risk.
Men at higher risks
There is considerable variability 
among men's values and 
preferences regarding prostate 
cancer screening. Men who place a 
high value in avoiding 
complications from biopsies and 
subsequent treatment are likely to 
decline screening. In contrast, men 
who place a higher value in even a 
small reduction of prostate cancer 
mortality may opt for screening. 
Higher risk patients may be more 
likely to seek screening because 
they may worry more about 
prostate cancer and want to rule 
out the diagnosis.
Values and preferences
LUTS symptoms like these are 
common complaints in adult men 
that can have a major impact on 
quality of life and substantial 
economic burden. The aetiology of 
LUTS is multifactorial, benign 
prostatic enlargement, due to 
hyperplasia, being the major cause. 
Evidence to date indicates that 
men with LUTS are at no higher risk 
of prostate cancer than men 
without LUTS.
Lower Urinary Tract 
Symptoms (LUTS) 
Key practical issues
PSA testing is done with a regular blood sample
Usually taken through rectum guided by ultrasound Takes about 5-10 minutes
Antibiotics given before procedure Local anaesthesia or sedation given before procedure
May have to stop blood thinners before procedure
Screening
If biopsy is required
Slow stream
Sensation of incomplete emptying
Increased urinary frequency
Family history of prostate cancer
African descent
Poorer socio-economic groups
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due to a non-cancerous enlargement or inflammation of 
the prostate.4 Many men have a raised PSA level without 
having cancer (that is, false positive results). Conversely, 
a substantial number of men with a low PSA level will 
subsequently be diagnosed with prostate cancer (false 
negative results).
Investigations after raised PSA
If PSA is raised, the test is usually repeated. Men with per-
sistently elevated PSA levels typically undergo a transrec-
tal, ultrasound-guided, core-needle biopsy of the prostate 
to test for prostate cancer (see main infographic). If cancer 
is detected in the biopsied tissue, management options 
include surgery, radiation therapy, hormonal treatment, 
active surveillance, or watchful waiting. Diagnostic imag-
ing studies such as ultrasonography, magnetic resonance 
imaging (MRI), bone scan, and computed tomography, 
are often also performed, especially in men presenting 
with higher risk disease, to check for disease spread.
Screening controversy
For many reasons, PSA screening remains controversial. 
Advocates often base their opinions on the European Ran-
domised study of Screening for Prostate Cancer (ERSPC), 
which suggests that screening may reduce the long term 
risk of prostate cancer-specific mortality by at least 9% 
(relative reduction).5 They also note that substantial obser-
vational evidence indicates a reduction in advanced dis-
ease and reduction in prostate cancer mortality, which 
they attribute to the introduction of PSA screening.6 
Opponents of PSA screening highlight the indolent natural 
course of prostate cancer, citing systematic reviews that 
reported little or no impact of PSA screening on overall 
and prostate cancer-specific mortality.7 Opponents also 
suggest that the harms and burden from overdiagnosis 
and overtreatment resulting in unnecessary prostate biop-
sies and impaired urinary, sexual, and bowel function as 
side effects of surgery or radiation therapy outweigh the 
uncertain and modest benefits.
Current guidelines on PSA testing
Guidelines vary in their recommendations on PSA test-
ing (see table 1). The Canadian Task Force on Preventive 
Health Care recommends against PSA screening for men 
aged 55 to 69 years.8 However, the US Preventive Services 
Task Force recently changed its guidance to say that “the 
Box 2 | Linked articles in this BMJ Rapid Recommendation 
cluster
• Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer 
screening with prostate-specific antigen (PSA) test: 
a clinical practice guideline. BMJ 2018:362:k3581. 
doi:10.1136/bmj.k3581
 – Summary of the results from the Rapid 
Recommendation process
• Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer 
screening with prostate-specific antigen (PSA) 
test: a systematic review and meta-analysis. BMJ 
2018:362:k3519. doi:10.1136/bmj.k3519
 – Systematic review and meta-analysis of all available 
randomised trials that assessed PSA based screening 
for prostate cancer
• Vernooij RWM, Lytvyn L, Pardo-Hernandez H, et 
al. Values and preferences of men for undergoing 
prostate-specific antigen screening for prostate cancer: 
a systematic review. BMJ Open 2018;0:e025470. 
doi:10.1136/bmjopen-2018-025470
 – Systematic review of the values and preference of men 
considering PSA screening
• MAGICapp (https://app.magicapp.org/public/
guideline/n32gkL)
 – Expanded version of the results with multilayered 
recommendations, evidence summaries, and 
decision aids for use on all devices
HOW THIS RECOMMENDATION WAS CREATED
Our international panel included patient partners (men 
at risk of prostate cancer), general practitioners, general 
internists, urologists, epidemiologists, methodologists, and 
statisticians. They determined the scope of the question that 
the recommendation should address and what outcomes 
are most important to patients considering screening.
No person had financial conflicts of interest; intellectual 
and professional conflicts were minimised and managed 
(see appendix 1 on bmj.com).
The panel identified eight critical outcomes needed 
to inform the recommendations: all-cause mortality; 
prostate cancer mortality; incidence of prostate cancer 
diagnoses (all stages); incidence of localised cancer (stage 
I and II); incidence of advanced cancer (stage III and IV); 
complications from biopsies (such as bleeding, pain, 
infections, and hospital readmissions), complications from 
prostate cancer treatment (such as urinary incontinence 
and erectile dysfunction); and quality of life. The panel also 
identified three additional patient-important outcomes: 
false positive rates (men with elevated PSA levels who 
will have negative biopsy); false negative rates (men with 
a normal PSA result who will subsequently be diagnosed 
with cancer), and the anxiety and uncertainty related to 
concerns about having prostate cancer. The panel asked that 
potential subgroups effects be explored according to age, 
screening interval, family history, being of African descent, 
and being of lower socioeconomic level. They also asked for 
a sensitivity analysis of the effect of screening restricted to 
trials at lower risk of bias.
To inform the recommendation, the panel members 
requested two systematic reviews, on the following 
questions:
• What are the benefits and harms of PSA screening versus 
no screening?1
• What evidence describes the values and preference of men 
considering PSA screening?29
Two parallel teams conducted these systematic reviews, 
which are linked to this publication.
The panel met to discuss the evidence and formulate 
a recommendation. They followed the BMJ Rapid 
Recommendations procedures for creating a trustworthy 
recommendation,43 including use of the GRADE approach 
to interpret the evidence and create recommendations 
(see appendix 2 on bmj.com).44 The panel considered the 
balance of benefits, harms, and burdens of PSA screening; 
the quality of the evidence for each outcome; and typical 
and expected variations in patient values and preferences, 
as well as feasibility and acceptability. Recommendations 
can be strong or weak, for or against a course of action. The 
recommendations take a patient-centred perspective which 
de-emphasises public health, societal, and health payer 
point of view.
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decision about whether to be screened for prostate cancer 
should be an individual one,” without clearly suggesting for 
or against screening9: previously it recommended against 
screening in that group. National Cancer Center Network 
(NCCN) guidelines (which represents cancer centres in 
the USA) recommends initiating PSA screening at age 45 
years.10 Guidelines from the American Urological Associa-
tion (AUA)11 and European Association of Urology (EAU)12 
recommend a discussion about PSA screening with patients.
Uptake of PSA testing
The incidence of prostate cancer has dramatically 
increased over the last quarter century. This has been 
associated with widespread use of prostate specific anti-
gen (PSA) testing detecting early stage prostate cancers.13 
There is wide variation in the adoption of prostate can-
cer screening. In the UK, about 39% of men aged 45-69 
years have undergone PSA testing in the past 10 years.14 
In Sweden 23% of men aged 50-69 had a PSA test in the 
previous 12 months and 58% in the previous 10 years.15 
Although the rates of screening have declined during the 
past decade in the US,16-18 up to half of US men aged 60-74 
undergo screening each year. Also, as many as 33% of 
elderly US men with competing medical comorbidities at 
high risk of dying from other cause underwent screening, 
and twice as many of these men recalled discussing the 
potential benefits rather than harms of screening.19 Afri-
can-Americans were less likely to have been screened than 
non-African US men.20 Overall, two thirds of men reported 
no past discussion with physicians about the advantages, 
disadvantages, or scientific uncertainty and no shared 
decision making about prostate cancer screening.20
The evidence
The updated systematic review on the benefits and harms 
of PSA screening pools data from five randomised con-
trolled trials (with ERSPC comprising eight European 
countries), which enrolled a total of 721 718 men (with 
419 582 included in the latest CAP trial).1
Main characteristics and limitations of the trials
Figure 2 provides an overview of the trials’ characteristics 
and the patients included. All trials had methodological 
limitations. In the CAP trial only 36% of men randomised 
to the screening arm actually underwent PSA testing (that 
is, low adherence to screening), while about 10-15% in 
the non-screening arm were actually tested (that is, con-
tamination). CAP also differed from other large scale trials 
in that it used one-time screening, whereas others used 
repeated screening with intervals varying from annual to 
every two years or more.
The Prostate, Lung, Colorectal and Ovarian (PLCO) 
Cancer Screening trial conducted in the US21 lacked allo-
cation concealment, and rates of PSA testing in the non-
screening arm exceeded 50%, possibly as high as 80%.22
The European Randomised Study of Screening for Pros-
tate Cancer (ERSPC) was conducted in eight European 
countries.5 There was possibly inadequate allocation 
concealment, and there are concerns that groups may 
have received different quality of treatment for prostate 
cancer (performance bias). Nevertheless, the systematic 
review authors judged the ERSPC trial to be the one that 
was probably least affected by bias. Based on a predefined 
sensitivity analysis,1 the BMJ Rapid Recommendations 
panel decided to appraise both the summary of the whole 
Table 1 | Major guideline recommendations on PSA screening*
Organisation, last published update Recommendation
US Preventive Services Task Force, 2018 Provide information about potential benefits and harms of screening for men aged 55-69 years
Recommend against screening for men aged ≥70 years
Canadian Task Force on Preventive Health 
Care, 2014
Recommend against routine screening 
 • Weak recommendation in men aged 55-69, and strong in other ages
American Cancer Society, 2016 Provide information about uncertainties, risks, and potential benefits of screening to enable informed 
decision making
Recommend screening discussions for: 
 • Men aged 50 years who are at average risk (expected to live at least 10 more years) 
 • Men aged 45 years who are at high risk (African-Americans, and men with a first degree relative with 
prostate cancer diagnosed at <65 years old) 
 • Men aged 40 years who are at very high risk (more than one first degree relative with prostate cancer 
diagnosed at <65 years old)
American Academy of Family Physicians, 
2012
Adopted the US Preventive Services Task Force 2012 recommendation, which recommended against 
screening
American Urological Association, 2015 Shared decision making for men aged 55-69 years
Recommend against routine screening in men aged <40 years or those with life expectancy <10-15 years
American College of Physicians, 2015 Shared decision making for men aged 50-69 years
Recommend against screening in men aged <50 or ≥70 years, those with life expectancy <10 years, and those 
who had not had informed discussion
US National Comprehensive Cancer Network, 
2018
Offer screening to men aged 45-75 years. Begin discussing PSA screening with African-American men several 
years earlier than white men. Continue screening beyond 75 years old with caution in healthy patients with 
little or no comorbidity
European Association of Urology, 2018 Recommend against PSA testing without prior counselling on potential risks and benefits
Offer an individualised, risk-adapted strategy for early detection to well informed men with good performance 
status and life expectancy ≥10-15 years
Recommend screening for men aged >50 years, or >45 years for men with positive family history or African-
American ethnicity.
Recommend against routine screening for men with life expectancy <15 years
European Society for Medical Oncology, 2015 Recommend against population based screening
UK National Screening Committee, 2016 Recommend against systematic population screening
*These guidelines have not taken account of the new evidence captured in our Rapid Recommendations.
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Fig 2 |  Characteristics of patients and trials included in systematic review of the use of the prostate-specific antigen (PSA) test for prostate cancer screening.1
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body of evidence as well as selected data at lower risk of 
bias from the ERSPC study (see main infographic).
Although most studies reported mortality and cancer 
incidence, there was limited randomised data on com-
plications from biopsies or subsequent prostate cancer 
treatment and on quality of life. The systematic review 
team therefore searched for available follow-up evidence 
from the intervention arms of included trials and follow-
up publications.
They used ERSPC sub-data for quality of life (that is, 
the Finnish arm of the study)23 and false positive rates.24 
They estimated false negative rates among men with a 
low PSA level from a follow-up cohort study of the Pros-
tate Cancer Prevention Trial.25 Complications rates from 
subsequent treatment modalities were obtained from 
the ProtecT trial embedded in the CAP trial—in which 
patients diagnosed with prostate cancer in the CAP 
screening trial were randomised to active monitoring, 
radical prostatectomy, or radical radiotherapy with hor-
mones.26 Similarly, complication rates from biopsies were 
obtained from the Prostate Biopsy Effects cohort study 
nested within the ProtecT trial.27 By modelling the likeli-
hood of elevated PSA values, biopsies, cancer diagnoses, 
and treatment modalities (from the NIH’s Surveillance, 
Epidemiology, and End Results (SEER) programme),28 the 
linked systematic review estimated the absolute number 
of biopsy and treatment related complications among 
men who underwent screening versus those who did not 
(see infographic and appendix 3 on bmj.com for more 
details). The quality of evidence assessment with GRADE 
considers the unique limitations in the evidence for each 
outcome.
Evidence on men’s values and preferences
Evidence suggests that different men judge the benefits 
and harms of PSA testing and its consequences differ-
ently. The linked systematic review on the values and 
preferences of men considering PSA screening29 included 
studies that reported quantitative data on the degree of 
benefits (such as reduction in mortality risk) that men 
would require and degree of harms (such as increase in 
risk of incontinence) that men would be willing to accept 
to undergo prostate cancer screening. Five studies were 
identified that investigated a direct choice related to PSA 
screening.29
The studies used different methodologies and varied 
considerably in how their outcomes were reported. One 
study showed that men were willing to forego screening 
with a benefit of 2% on prostate cancer mortality if it 
increases their probability of avoiding unnecessary biop-
sies by 10% or avoiding unnecessary treatment by 10%.30 
In another study, men were willing to accept between 65 
and 233 per 10 000 unnecessary biopsies to avoid one per 
10 000 prostate cancer deaths. These results varied with 
age: men in their 50s were willing to accept more unnec-
essary biopsies than men in their 40s or in their 60s.31
The review also included six studies in which men were 
presented with decision aids showing outcomes such as 
prostate cancer diagnosis and prostate cancer mortality. 
Willingness to undergo screening varied from 37% in a 
study displaying a reduction in mortality of 10 per 1000 
men to 44% in a study displaying a reduction in mor-
tality of 7 per 1000.29 The review found no studies that 
specifically investigated whether the men’s values and 
preferences differed among men with a family history of 
prostate cancer, men of African descent, or men of lower 
socioeconomic class.
Understanding the recommendation
The recommendation against PSA screening is weak 
because of the small and uncertain benefits of screen-
ing on prostate cancer mortality and the large variabil-
ity in men’s values and preferences. In practice, a weak 
recommendation means that shared decision making is 
important. Clinicians should support men considering 
screening to make a well informed decision in line with 
their own risk profile and individual values and prefer-
ences. Another implication of our weak recommendation 
is that clinicians do not need to raise the issue systemati-
cally with their patients. They could raise PSA screening 
or wait for the patient to raise the issue. Both approaches 
are reasonable. It depends on the patient’s context and 
competing issues in each clinical encounter.
The panel believes that most informed men considering 
screening would decline it, although some would choose 
to undergo screening, accepting the diagnostic and thera-
peutic burden and harms that can result.
Absolute benefits and harms
The main infographic explains the recommendation and 
provides an overview of the absolute benefits and harms 
of screening at a 10 year time horizon for consistency and 
easier communication. However, the individual trials var-
ied in their duration of follow-up from 10 to 20 years (fig 
2), and we used the relative estimates of effect, pooled 
in the linked systematic review, at the longest available 
follow-up time.1 For the 10 year time horizon, we used as 
baseline risk in the non-screening arm of the CAP trial. It 
provided the most contemporary estimates of risks from 
a large sample of men representative of a general practice 
setting.2
Death and cancer diagnosis
PSA screening may increase the detection of prostate 
cancer (7 more per 1000 men (95% confidence interval 
1 to 15 more) at 10 years), particularly of localised can-
cer (7 more per 1000 men (2 to 15 more)). But the data 
show no difference in prostate cancer mortality. Overall 
confidence in these estimates across these outcomes was 
low because of risk of bias as well as the inconsistency of 
findings across studies.
When focusing on studies at lower risk of bias—ERSPC 
trials—the panel was confident that over a 10 year period:
•   PSA screening probably has little or no effect on 
death
   – All-cause mortality (0 fewer per 1000 men (95% CI 
3 fewer to 3 more))
   – Prostate cancer mortality (1 fewer per 1000 (1 to 0 
fewer))
   – Prostate cancer mortality is similar at longer 
periods of up to 18 years of follow-up (1 to 2 fewer 
per 1000 men)1
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•   PSA screening probably increases diagnosis of 
prostate cancer
   – Detection of any prostate cancer (18 more per 1000 
men (16 to 20 more))
   – Detection of localised cancer (14 more per 1000 
(13 to 16 more))
   – But it probably results in a small decrease in 
detection advanced prostate cancer (3 fewer per 
1000 (4 to 2 fewer)).
The panel was also confident that:
•   About two thirds of men offered a biopsy because 
of an elevated PSA result will have normal biopsy 
results and no prostate cancer (that is, false 
positive results of PSA screening)
•   About 15% of men with a normal PSA result will 
subsequently be diagnosed with prostate cancer; 
with about 2% of men with a normal PSA result 
diagnosed with advanced cancer (that is, false 
negative results of PSA screening)
•   Each biopsy bears a substantial risk of side effects 
and serious complications, including blood in 
semen (93%), blood in urine (66%), pain (44%), 
fever (18%), and admission to hospital for sepsis 
(1-2%).
Thus, considering that about one in seven men who 
undergo PSA screening will have an elevated PSA result2 5 
and most of them will undergo biopsy (about 85% in the 
CAP and ERSPC trials, see appendix 3 on bmj.com):
•   Among a hypothetical population of 1000 men, 
about 94 more will present with blood in the 
semen with PSA screening, 67 more with blood 
in the urine, 45 more with pain, 19 more with 
fever, and 1 more hospitalised for sepsis, due to a 
prostate biopsy
•   The panel acknowledges uncertainty in these 
projected estimates, as they were based on 
modelling and several assumptions in the rates 
of biopsies and cancers detected in men that were 
screened and in those who were not. These are 
likely to vary across clinical contexts and diagnostic 
strategies. For example, new approaches (including 
genetic or biomarkers, risk stratification tools, 
and MRI-guided biopsy32-34) have the potential for 
avoiding biopsies in men with non-progressive and 
slowly progressive cancer, and thus diminish the 
likelihood of harm from their complications when 
entering screening through PSA testing. However, 
the impact of such modalities on patient-important 
outcomes remains uncertain.
Harms linked to management of prostate cancer
The panel was confident in the complications rates 
reported for treatments of prostate cancer, in particular:
•   Urinary incontinence (pad use at 6 years after 
treatment) was present in 17% of men who had 
surgery, 4% who had radiotherapy, and 8% of men 
under active surveillance
•   Erections not firm enough for intercourse were 
present in 83% of men who had surgery, 73% 
who had radiotherapy, and 70% under active 
surveillance.
Thus,
•   Applying these numbers to a hypothetical 1000 
men,28 about three more will present with urinary 
incontinence (any pad use) and 25 more will 
have an erection not firm enough for intercourse 
due to treatment for prostate cancer diagnosed 
through PSA screening (see appendix 3). Once 
again, the panel has low confidence in these 
projected estimates, as they are based on several 
assumptions depending on the particular context 
and required data modelling. New diagnostic 
strategies could also shift the proportions of men 
who enter active surveillance rather than radical 
surgery or radiotherapy.
Quality of life
The panel was less confident about the impact of screen-
ing on the overall quality of life or the anxiety of having 
cancer:
•   There was no difference in quality of life between 
men who undergo PSA screening and those who 
do not. But this comparison was available only in a 
subset of men from one of the trials (n=1088, more 
details through the MAGICapp within the main 
infographic).23
•   There is no randomised evidence comparing 
PSA screening with non-screening in regard to 
the anxiety related to a cancer diagnosis. A large 
cohort study in Sweden among 4.3 million men 
showed an increased risk of suicide (relative 
risk 2.6 (95% CI 2.1 to 3.0)) and cardiovascular 
events (1.3 (1.3 to 1.3)) during the first year after 
diagnosis.35 A US cohort study with 343 000 men 
showed no increased risk of suicide during the first 
year after the widespread use of PSA screening 
(after 1993) but an increased risk of cardiovascular 
death during the first month after diagnosis 
(adjusted relative risk 1.55 (1.3 to 1.8)).36 Thus it 
remains uncertain whether screening results in 
changes in anxiety about cancer.
Adapting the offer for men at higher risk of prostate 
cancer and death
The linked systematic review did not find a relative sub-
group effect by age: the effects of screening are consistent 
across age strata.1 Age of men enrolling in the stud-
ies ranged from 45 to 80 years, with most aged 50-69 
years. The panel believes the evidence thus applies to 
men regardless of age. However, any possible benefit of 
screening is likely to become negligible as life expectancy 
decreases due to age or comorbidities.
There were no randomised data on whether screening 
efficacy differed in those with a family history of pros-
tate cancer, men of African descent, or men from lower 
socioeconomic levels. It remains uncertain whether the 
relative effect of screening is similar to that in the general 
population. However, these factors are associated with 
higher incidence of prostate cancer and higher risk of 
prostate cancer death in observational studies, as well 
as in follow-up publications of the trials included in the 
linked review (Finnish37 38 and Swiss39 arms from the 
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ERSPC trial and the PLCO trial40). Using evidence from 
these trials, we adapted the baseline risk in our summary 
of findings, using the same studies at lower risk of bias 
(that is, ERSPC data). In these studies, family history was 
assessed by self reporting in a questionnaire and defined 
positive if a man reported that his father or at least one 
brother had been diagnosed with prostate cancer.37 39 For 
race or ethnicity, non-Hispanic black men were compared 
with non-Hispanic white men.40 Level of education was 
used as a proxy for socioeconomic status, and men with 
primary education only were defined as having a low level 
of education and men with secondary or tertiary educa-
tion defined as having high level of education.38
For men of African descent, over a 10 year period:
•   The baseline risk of developing prostate cancer of 
any stage is likely higher than that of the general 
population (estimated at about 51 per 1000 men 
diagnosed), and PSA screening probably increases 
their detection of any stage cancer by a larger 
magnitude than in the general population (29 
more per 1000 men (95% CI 26 to 32 more))
•   Baseline risk of prostate cancer mortality is likely 
also higher than in the general population of 
men considering screening (estimated at about 7 
per 1000 men dying at 10 years). However, PSA 
screening had a similar small effect in reducing 
prostate cancer mortality in absolute terms (1 
fewer per 1000 (2 to 1 fewer)).
For men with family history, over a 10 year period:
•   As for men with African descent, the baseline risk 
of developing prostate cancer is likely higher than 
in the general population (estimated at about 50 
per 1000 men diagnosed with any stage prostate 
cancer; and about 25 per 1000 are localised 
cancers). PSA screening probably increases their 
detection of any stage cancer (29 more per 1000 
(26 to 31 more)) as well as localised cancers (19 
more per 1000 (17 to 21 more))
•   These baseline risk estimates are based on 
studies that defined family history as positive 
if a man reported that his father or at least one 
brother had been diagnosed with prostate cancer. 
These baseline risk estimates may increase with 
increasing number of relatives diagnosed with 
prostate cancer.41
For men with lower level of education, over a 10 year 
period:
•   There was limited data on how much more these 
men were at higher baseline risk. Using lower level 
of education as a proxy of lower socioeconomic 
status,38 we estimated that baseline risk of 
prostate cancer mortality was higher (about 4 per 
1000 men dying at 10 years) as well as all-cause 
mortality (about 196 per 1000 men)
•   The absolute effect of PSA screening is overall 
comparable to that in the other subgroups, with a 
small reduction in prostate cancer mortality (about 
1 fewer per 1000 men (1 to 0 fewer))
•   PSA screening probably has little or no effect on 
all-cause mortality (about 4 fewer per 1000 (10 to 
0 fewer)).
Values and preferences
The panel, including the patient partners, felt that this 
variability in values and preferences contributes to a 
weak recommendation. The recommendation against 
screening reflects a belief that most men would value 
avoiding complications from biopsies and subsequent 
treatment because the reduction in prostate cancer and 
death from screening is small and uncertain. Prostate 
cancer will often, though not always, remain indolent.
Men who place a high value on avoiding complica-
tions from biopsies and subsequent treatment are likely 
to decline screening. In contrast, men who place a higher 
value on even a small reduction of prostate cancer may 
opt for screening. Several panel members felt that higher 
risk patients—such as patients with family history of 
cancer or of African descent—may be more likely to seek 
screening because they may worry more about prostate 
cancer and want to rule out the diagnosis.
For men considering screening, shared decision making 
is critical to ensure that their decision is in line with their 
own values and preferences. The evidence summarised 
in this Rapid Recommendation is available in MAGICapp 
as decision aids that can support shared decision making 
(https://app.magicapp.org/public/guideline/n32gkL).
Practical issues and other considerations
Figure 3 outlines the key practical issues. PSA testing can 
be performed on any normal blood sample, but prostate 
biopsies and their follow-up have important implications 
for daily life.
Lower urinary tract symptoms (slow urine stream, 
sensation of incomplete emptying, increased urinary fre-
quency) are common complaints in adult men that can 
have a major impact on quality of life. Benign prostatic 
enlargement is the major cause. Evidence to date indi-
cates that men with these complaints are not at increased 
risk of prostate cancer.4
For men who chose to undergo PSA testing, the optimal 
frequency of screening remains unknown. Figure 2 sum-
marises the frequency used in the different trials, yet the 
accompanying systematic review did not find any signifi-
cant subgroup effect of the effect of screening based on 
these different frequencies.1 Given that the ERSPC data 
are likely at lower risk of bias, PSA screening every four 
years—rather than, say, every year or only once in a life-
time—may be the optimal interval.
Costs and resources
Results from a recent cost-effectiveness study modelled 
for the US suggested that screening between the ages of 
55 and 69 years combined with active surveillance for 
low risk men could only be cost-effective at a $100 000 
threshold if the screening frequency remains low (every 
four years) and active surveillance is offered to all men 
with low risk prostate cancer (that is, Gleason score ≤6 
and stage ≤T2a). Strategies with shorter screening inter-
vals or in which immediate treatment is offered to all men 
were not cost-effective.42 Although the Rapid Recommen-
dations panel focused on the patients’ priorities rather 
than those of society, our recommendation is compatible 
with these findings.
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PRACTICAL ISSUES
Biopsy
MEDICATION
ROUTINE
PSA testing
EMOTIONAL
WELL-BEING
COSTS &
ACCESS
TESTS & VISITS
PROCEDURE &
DEVICE
RECOVERY &
ADAPTATION 
COORDINATION
OF CARE
ADVERSE EFFECTS,
INTERACTIONS &
ANTIDOTE
PHYSICAL
WELL-BEING
SOCIAL LIFE &
RELATIONSHIPS
TRAVEL TIME
& DRIVING
EXERCISE &
ACTIVITIES
WORK &
EDUCATION
Prostate biopsy is normally done in outpatient 
clinic/hospital
May have to stop blood thinners before prostate biopsy 
procedure
Waiting for prostate biopsy results can be stressful
Prostate biopsy is usually taken through rectum guided 
by ultrasound
Takes about 5-10 minutes
Antibiotics and local anaesthesia/sedation given 
before procedure
Allow for some recovery time dependent on adverse 
effects after prostate biopsy
Need for someone to drive you home after prostate 
biopsy procedure if sedation is given
Prostate biopsy often leads to soreness, blood in 
semen, urine and stool for days to
weeks
Prostate biopsy procedure can be 
uncomfortable
Cost depends on health policy and health 
insurance; sometimes expensive
Avoid vigorous exercise or physical activities after 
prostate biopsy
Blood in semen and pain in pelvic area can impact 
sexual life after prostate biopsy
Need to take time off work to do prostate biopsy 
procedure
Should not drive directly after prostate biopsy 
procedure if sedation is given
Blood sample, often taken at GP/family physician
Waiting for PSA results can be stressful
Cost depends on health policy and health 
insurance; usually not expensive
Avoid vigorous exercise (such as cycling) in the 2 
days prior to PSA testing, as this may result in false 
positive elevation
Avoid ejaculation in the 2 days prior to PSA testing, 
as this may result in false positive elevation
PSA testing is done with a regular blood sample
Elevated results can lead to further diagnostics 
or additional tests
Some drugs (finasteride, dutasteride) can lower PSA 
levels
Minimal discomfort associated with the blood draw
Need to take time off work for PSA testing
Fig 3 |  Practical issues about use of prostate-specific antigen (PSA) testing and biopsy for prostate cancer screening
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Uncertainties for future research
Recent evidence suggests that incorporating MRI in the 
investigation of those with a positive PSA test result 
decreases the false positive rate, and thus the number 
of patients undergoing unnecessary biopsies, and may 
also increase the accuracy of biopsies in those who do 
have prostate cancer. The Rapid Recommendations panel 
considered addressing this issue in the guideline, but the 
impact of MRI on long term outcomes of prostate can-
cer incidence, mortality, and complications of treatment 
remains uncertain. Sophisticated decision modelling 
might shed light on this issue, but the panel decided not 
to conduct such an analysis because of logistic and fea-
sibility considerations, and because the panel’s review 
of the evidence suggests that modelling would introduce 
further uncertainties regarding the impact of MRI on 
patient-important outcomes.
Key research question to inform decision makers and 
future guidelines include
•   Could new screening and diagnostic techniques 
reduce the harms and burden of the diagnostic 
procedure by better identifying non-progressive and 
slowly progressive cancer from cancer that is likely 
to become symptomatic and affect quality or length 
of life? These strategies may include genetic markers 
or biomarkers, risk stratification tools, or MRI guided 
biopsy.32 For example, two recent high quality studies 
on MRI guided biopsy have shown encouraging 
results of MRI to reduce overdiagnosis,33 34 but 
the impact of this strategy on long term, patient-
important outcomes (such as prostate cancer 
incidence, mortality, and complications of treatment) 
remains uncertain.
•   For men opting for screening, what would be the 
ideal age range and screening interval? Randomised 
trials varied in their offer of a one-off or repeated PSA 
testing and it remains uncertain which strategy is 
more suitable.
•   What is the impact of screening on men at higher 
baseline risk (men with a family history of cancer, of 
African descent, and of lower socioeconomic status)? 
Are their values and preferences different from those 
of men in the general population?
Updates to this article
The final table shows evidence that has emerged since the 
publication of this article. As new evidence is p ublished, 
a group will assess the new evidence and make a judg-
ment on the extent it is expected to alter the recommen-
dation.
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